Today, in the Immunex v. Sandoz patent litigation under the BPCIA concerning Sandoz’s Erelzi (etanercept-szzs) biosimilar, New Jersey District Judge Claire C. Cecchi issued an order that trial will commence on September 11, 2018. (Trial had originally been slated to begin this month.) The Court also ordered the parties to submit by May 15, 2018, a joint letter to the Court setting forth any agreements reached by the parties to streamline the issues for trial and/or any outstanding issues requiring resolution by the Court.
Immunex’s motion for summary judgment of infringement remains pending.
Stay tuned to Big Molecule Watch for further developments.
The post Etanercept Biosimilar Trial Rescheduled to September appeared first on Big Molecule Watch.